Transcriptional transactivator peptide modified lidocaine-loaded nanoparticulate drug delivery system for topical anesthetic therapy.

Purpose: For the topical anesthetic, transcriptional transactivator peptide (TAT) modified lidocaine (LID) loaded nanostructured lipid carriers (TAT-NLCs-LID) were prepared and then used for improving transdermal delivery of local anesthetic drug.

Methods: In this study, TAT was conjugated with Distearoyl phosphatidylethanolamine-(polyethylene glycol)-maleimide (DSPE-PEG-Mal) to obtain TAT-PEG-DSPE. TAT-NLCs-LID were successfully prepared and characterized by determination of their particle size, morphology, drug encapsulation efficiency and in vitro drug release behavior.

TRPA1 ion channels in vagal afferent nerves contribute to ventilator-induced lung injury in a rat model.

In order to investigate the effects of transient receptor potential channel A1 (TRPA1)-mediated neurogenic inflammatory reaction on the process of ventilator-induced lung injury (VILI). A rat VILI model was created, and the TRPA1 selective antagonist, HC-030031, was used to investigate the role of TRPA1 in the process of VILI. 50 rats were randomly divided into five groups: vehicle group, low tidal volume group, high tidal volume group, low tidal volume group with TRPA1 inhibitor, high tidal volume group with TRPA1 inhibitor.